SCHEMBL24166208

SCHEMBL24166208

Cn1cc(-c2cc3c(C=O)c([N+](=O)[O-])cnc3n2S(=O)(=O)c2ccccc2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.42
PDPK1 O15530 1/20 0.36
FGFR1 P11362 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
HDAC3 O15379 1/20 0.35
KDM1A O60341 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
GAA P10253 2/20 0.35
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24165287 0.94 ERN1 (0.36) ERN1PDPK1FGFR1PTGDR2HDAC3
SCHEMBL24165525 0.90 DCTPP1 (0.39) ERN1PDPK1FGFR1PTGDR2HDAC3
SCHEMBL24165519 0.85 HDAC3 (0.40) PDPK1FGFR1HDAC3KDM1AHDAC1
SCHEMBL31089804 0.82 PDPK1 (0.38) ERN1PDPK1FGFR1HDAC3KDM1A
SCHEMBL24165515 0.81 ERN1 (0.38) ERN1PDPK1FGFR1PTGDR2HDAC3
SCHEMBL21470471 0.77 FGFR1 (0.42) PDPK1FGFR1HDAC3KDM1AHDAC1
SCHEMBL17289609 0.77 PDPK1 (0.40) PDPK1FGFR1PTGDR2WNT1GSK3B
SCHEMBL15661963 0.77 PDPK1 (0.38) PDPK1FGFR1HDAC3KDM1AHDAC1
SCHEMBL16809715 0.77 PDPK1 (0.37) PDPK1FGFR1HDAC3KDM1AHDAC1
SCHEMBL24165520 0.76 HTR2A (0.38) KMT2AMEN1MAPTPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767323-B2 Tricyclic pyridone compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-09-26 US disclosed
US-11767323-B2 Tricyclic pyridone compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-09-26 US disclosed
US-20220002299-A1 TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2022-01-06 US disclosed
WO-2022006456-A1 TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION (US) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002299-A1 TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS JAK2, JAK1, JAK3 ERN1 1877/4885PDPK1 255/4885FGFR1 831/4885
US-11767323-B2 Tricyclic pyridone compounds as JAK2 V617F inhibitors JAK2, JAK1, JAK3 ERN1 1877/4885PDPK1 255/4885FGFR1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.